Pharmaceuticals

A major merger backed by private equity signals a new era for pharmaceutical training, blending AI, behavioral science, and launch expertise to tackle industry complexity.

With a novel non-hallucinogenic drug, Enveric Biosciences heads to the BIO convention seeking partners. Can its unique science secure its future?

The PD-L1 biomarker testing market is set to double by 2036, fueling a revolution in cancer care. But as innovation races ahead, who gets left behind?

A new manufacturing patent for pelareorep de-risks Oncolytics' path to market, protecting the drug until 2044 and signaling commercial readiness.

A major survey names Bonafide Health's products #1 in their class. We explore the strategy behind the headlines and what it signals for women's health.

A record $1.15M campaign for blood cancer reveals a new playbook where executive influence, not just corporate checks, drives profound social impact.

Eli Lilly's strategic buyout of a Texas biotech isn't just a deal; it's a bet on a new scientific paradigm to solve the chronic pain crisis without opioids.

Quoin Pharma's new data for a rare skin disease shows life-changing results in children, offering hope for families. What do the numbers really mean?

With veteran investor Travis Read as new President & COO, AmMax Bio signals a major push to accelerate its promising antibody-drug conjugate pipeline.

A new partnership between Innoviva and Dr. Reddy's aims to bring a vital antibiotic, XACDURO®, to regions where a deadly hospital infection is rampant.

Adial Pharmaceuticals pivots from addiction to inflammation, securing $32M and poaching Azora's leadership to drive its new ulcerative colitis drug, AT177.

Eli Lilly's Zepbound secures a landmark approval for sleep apnea, moving beyond weight loss to redefine chronic disease management and challenge competitors.

BioAge Labs starts a Phase 2 trial for BGE-102, an oral drug targeting inflammation to reduce heart risk, a strategy that could redefine cardiovascular care.

LRM Aesthetics' new delivery system for its PDGF+ formula isn't just a product update; it’s a masterclass in how small innovations create major workflow gains.

A biotech firm's non-hallucinogenic drug just passed a key safety test. Could this novel approach finally disrupt the challenging world of alcohol use disorder?

A new patent gives Cognition Therapeutics’ lead drug candidate protection until 2045. Here’s why this strategic move is about more than just IP.

Acumen Pharmaceuticals unveils two new candidates using a novel technology to deliver therapies directly to the brain, promising a more effective fight against AD.

A new pact between Canada’s CASTL and Ireland’s NIBRT, backed by top leaders, aims to solve a critical talent shortage and secure the global pharma supply chain.

The 8th annual 'Shine the Light' campaign unites 47 groups to fight Sickle Cell Disease, but behind the red-lit landmarks lies a deeper crisis of access to new, multi-million dollar cures.

Pharma giant MSD and health-tech innovator Nivi are using an AI chatbot to fight cervical cancer in Asia. Can this model overcome regulatory hurdles and scale?